

**Remarks:**

Claims 5, 9, and 30 - 45, were allowed pursuant to the Examiner's Amendment mailed on March 21, 2008. Applicants have amended claims 4 and 45, in view of the Examiner's Amendment; and added new claim 46, which Applicants wish to be considered.

Applicants have entered the amendments, including the cancellation of the previously withdrawn claims, requested in the Examiner's Amendment which accompanied the Notice of Allowance, however, Applicants have taken the Markush group which used to be in claim 45 and divided it into two independent claims, thus amending claim 45 to limit the claim to one group of the two groups previously specified in claim 45, and adding claim 46 to incorporate the second group. Applicants further note that the term "sequence" was inserted between the terms "nucleotide" and "encoding" into new claim 46 in order to more clearly define the claimed invention. Therefore, Applicants assert that there is no change in the scope of the claims and entrance of the amendment does not require a substantial amount of work on the part of the Patent Office. Applicants contacted the Examiner on June 3, 2008 to discuss this amendment and the Examiner agreed to consider the proposed amendments, pending approval from the Supervisory Examiner. Accordingly, Applicants respectfully assert that all claims as they now stand are patentable, allowable and a response to the Petition and accompanying amendments under 1.312 is courteously solicited, so that the issue fee can be paid and the Application can issue as a patent. Please contact the undersigned if any questions remain.

Any additional fee which is due in connection with this amendment should be applied against our Deposit Account No. 50-1662.

Respectfully submitted,

By /Tracey Truitt/

Tracey S. Truitt, Reg. No. 43,205

POLSINELLI SHALTON FLANIGAN SUELTHAUS

700 W. 47<sup>th</sup> Street, Suite 1000

Kansas City, Missouri 64112

816-753-1000